Summary: The Wound Care Today Learning Zone hosts a dedicated CPD e-learning module on the Debrisoft family of monofilament fibre debridement devices, produced in partnership with Lohmann & Rauscher (L&R), the manufacturer of the Debrisoft product range. The module covers the main features and benefits of Debrisoft Pads and the Debrisoft Lolly (a monofilament fibre pad with an ergonomic handle for hard-to-reach wounds), and provides guidance on correct use. Debrisoft’s monofilament fibre technology works by physically disrupting and lifting devitalised tissue, slough, biofilm, fibrinous deposits, and debris from wound beds and periwound skin through circular or sweeping motion, with the device hydrated with saline or wound cleanser prior to application. The technology received a positive recommendation from the National Institute for Health and Care Excellence (NICE Medical Technology Guidance MTG17) for use in acute and chronic wounds in community and clinic settings, based on clinical evidence of rapid and effective mechanical debridement with minimal patient discomfort and demonstrated cost savings versus saline/gauze, hydrogel, and larval therapy. Key supporting evidence includes: a 2021 prescribing audit by Burnett et al. (J Wound Care 30(5):381–388, DOI: 10.12968/jowc.2021.30.5.381) in 486 NHS patients showing reduced wound-care prescribing costs following Debrisoft introduction; a 2018 multicenter user test by Dissemond et al. (J Wound Care 27(7):421–425) across 155 wounds evaluating the Debrisoft Lolly for hard-to-reach wound debridement; and a 2018 ex vivo and clinical study by Schultz et al. (J Wound Care 27(2):80–90) demonstrating effectiveness at removing biofilm and slough. The Debrisoft Duo product extends the original Pad with a dual-sided design: the original soft white monofilament side for debris, exudate, and biofilm removal, and a textured beige side for loosening firmly adherent fibrinous slough. The module is freely accessible to registered Wound Care Today users and offers CPD certification upon completion.
Key Highlights:
- Monofilament technology: Debrisoft’s densely packed monofilament fibres reach into the wound bed and periwound skin to physically disrupt and remove necrotic tissue, biofilm, fibrinous slough, dry skin, and keratosis — while sparing newly formed granulation tissue and epithelial cells
- NICE MTG17 endorsement: the only mechanical debridement technology to receive NICE Medical Technology Guidance for community use; cost-saving analysis showed £77–£222 savings vs. hydrogel, £97–£347 vs. saline/gauze, and £180–£484 vs. larval therapy per patient
- Debrisoft Lolly: ergonomic handle design for debridement of cavities, sinuses, tunnelling wounds, body folds, and other anatomically challenging wound locations — evaluated in 155 wounds across 20 international centres by Dissemond et al.
- Biofilm relevance: Schultz et al. (2018) demonstrated ex vivo removal of mature biofilm from porcine dermal tissue, supporting Debrisoft’s role within biofilm-based wound care (BBWC) and wound bed preparation (TIME/TIMERS framework)
- Prescribing impact: Burnett et al. (2021) NHS audit of 486 patients found that introduction of Debrisoft monofilament debridement pad was associated with measurable reductions in wound-care prescribing costs over 6 months — providing real-world economic evidence beyond the NICE modelling
- Module access: freely available after registration at woundcare-today.com/learning-zone; CPD certification awarded on completion — suitable for district nurses, tissue viability nurses, and wound care clinicians seeking structured learning on mechanical debridement tools
Keywords: Debrisoft wound debridement, monofilament debridement pad, wound bed preparation debridement, NICE wound debridement guidance, biofilm mechanical debridement, CPD wound care education